Anticholinergic medicines linked to cardiovascular events in older adults
BMJ 2023; 382 doi: https://doi.org/10.1136/bmj.p2133 (Published 27 September 2023) Cite this as: BMJ 2023;382:p2133Linked research
Association between recently raised anticholinergic burden and risk of acute cardiovascular events: nationwide case-case-time-control study
Linked research
Future-case control crossover analysis for adjusting bias in case crossover studies
- Tou-Yuan Tsai, emergency physician12,
- Ching-Hui Loh, professor of geriatric medicine23,
- Huei-Kai Huang, physician-scientist24
- 1Emergency Department, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan
- 2School of Medicine, Tzu Chi University, Hualien, Taiwan
- 3Center for Aging and Health, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan
- 4Department of Family Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 97002, Taiwan
- Correspondence to: H-K Huang drhkhuang{at}gmail.com
Polypharmacy is prevalent among older adults aged ≥65 years and often leads to unintended clinical consequences. Drugs with anticholinergic activity are frequently prescribed to older adults for a range of conditions, such as respiratory, cardiovascular, gastrointestinal, and genitourinary diseases, and mental disorders. However, anticholinergic activity is often considered an unwanted side effect, causing adverse events such as urinary retention, mouth dryness, constipation, cognitive decline, and falls.123
Previous epidemiological studies indicate that about 20-50% of older adults regularly receive drugs with anticholinergic effects, and one third to one half of the drugs commonly prescribed to older adults exhibit potential anticholinergic activity.34 Therefore, recognising the anticholinergic burden and its potential negative impacts on older people is important clinically. The linked study by Huang and colleagues (doi:10.1136/bmj-2023-076045) contributes to a growing body of evidence by establishing an association between recently increased anticholinergic burden and a heightened risk of acute cardiovascular events, including myocardial infarction, stroke, arrhythmia, and cardiovascular death in older adults.5
Using nationwide population …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.